SEC Filing Summary: LabStyle Innovations Corp.
Business Context and Reporting Period
This Form 8-K was filed by LabStyle Innovations Corp. on May 15, 2015. The report serves as a current disclosure regarding the availability of the proxy statement for the Company's 2015 Annual Meeting of Stockholders, scheduled for June 15, 2015. The Company is incorporated in Delaware and maintains its principal executive offices in Caesarea Industrial Park, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding corporate governance materials and does not contain financial performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary event is the distribution of the proxy statement for the upcoming annual meeting.
Guidance, Outlook, and Risks
The filing explicitly states that the Company does not have securities registered pursuant to Section 12 of the Exchange Act of 1934. Consequently, it is not subject to the filing requirements related to proxy statements under Section 14 of the Act. The information provided is furnished under Regulation FD and shall not be deemed "filed" for the purpose of Section 18 of the Act, nor shall it be incorporated by reference into any registration statement. No specific guidance, outlook, or risk factors are detailed in this text.
Key Facts for Investor Verification
- The Company is LabStyle Innovations Corp., not Dariohealth Corp. (as indicated in the request metadata).
- The filing is a procedural notice for the 2015 Annual Meeting of Stockholders to be held on June 15, 2015.
- The Company is not subject to Section 12 registration requirements under the Exchange Act of 1934.
- The proxy statement is attached as Exhibit 99.1 but is not deemed "filed" for liability purposes under Section 18.